Case Study

In a land where drugs for ultra-rare indications are the new blockbusters, Alexion's Soliris is king.

Compared with the long time horizons and diminished returns of traditional antibody startups, Ablexis gave investors a deal they couldn't refuse.

Why did Geron—corporate standard bearer for regenerative medicine—fail, whereas technology pioneers in other areas persist?